etherna immunotherapies

Recent Finacing

Series B

Recent Raise

$38.4M

eTheRNA develops mRNA immunotherapies using TriMix, a three-mRNA immune-activating platform, and a proprietary intravenous lipid nanoparticle (LNP) delivery system for cancer and cross-strain SARS-CoV-2 vaccines.

Founded 2013

Antwerpen, Belgium

51-100

Private

etherna.be

Highlights

Focus Areas

Biotechnology

Health Care

Medical Device

Therapeutics

Recent Investors

G

Financials

$38.4M

Total Raised

1

Funding round

9

Investors

Team

Upgrade to view the team

See the team members at etherna immunotherapies.